Clarithromycin prophylaxis against Cryptosporidium enteritis in patients with AIDS.
Cryptosporidium enteritis (CE) in patients with acquired immunodeficiency syndrome (AIDS) can be a life-threatening opportunistic infection. A retrospective review of 471 charts of patients with AIDS in our clinic, prior to the availability of clarithromycin for the treatment of Mycobacterium avium complex (MAC), revealed that seven patients with CD4 counts < 25/mm3 developed CE. The median survival period from diagnosis to death in these patients was 10.6 days. The incidence of CE in patients with CD4 counts < 50/mm3 treated with clarithromycin prophylaxis for MAC was compared with patients not receiving clarithromycin prophylaxis. Of 136 patients with AIDS, 63 received clarithromycin 500 mg twice daily, and 73 patients not treated with clarithromycin represented the control group. None of the patients who received clarithromycin developed CE compared with four patients who developed CE in the control group. All four patients in the control group who developed CE had CD4 counts < 25/mm3. All patients who received clarithromycin remained stool negative for Cryptosporidium. In a subsequent 2-year follow-up of an additional 217 AIDS patients with CD4 counts < 50/mm3 receiving clarithromycin 500 mg twice daily as MAC prophylaxis, no patient developed CE. These results provide strong evidence supporting the use of clarithromycin as prophylaxis against cryptosporidium enteritis in patients with AIDS.
Jordan
W C
WC
Dept of Internal Medicine and Family Practice, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control*; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000276:immunology; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use*; D003457:Cryptosporidiosis / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy / Q000517:prevention & control; D012189:Retrospective Studies
D000900:Anti-Bacterial Agents; D017291:Clarithromycin